MedTrace Logo

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

NCT02654483 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2020-03-23

Study results available
· View outcomes & findings →

Summary

Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).

Conditions

Interventions

DRUG

VPD-737

VPD-737 inhibits the receptor neurokinin-1.

OTHER

Placebo

Matching tablets to VPD-737 tablets without active drug

Sponsors & Collaborators

  • Epidermolysis Bullosa Research Partnership

    collaborator OTHER_GOV

  • Vyne Therapeutics Inc.

    collaborator INDUSTRY

  • Jean Yuh Tang

    lead OTHER

Principal Investigators

  • Jean Tang, MD, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2018-06-28
Completion
2018-07-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02654483 on ClinicalTrials.gov